WATERS CORPORATION Reports Fourth Quarter FY 2022 Earnings Results for December 31, 2022 on February 15, 2023.
April 9, 2023
Earnings Overview
On February 15, 2023, WATERS CORPORATION ($NYSE:WAT) released its financial results for the fourth quarter of FY 2022 (ending December 31, 2022). Total revenue climbed 5.0% year-over-year to USD 227.1 million, while net income rose 2.6% to USD 858.5 million.
Transcripts Simplified
The company announced a 1.36 billion dollar investment that is expected to immediately increase revenues and operating margins. The closure is expected in the second quarter of the year, and quarterly financial results include an 8% growth in the Americas, 7% growth in Asia and 11% growth in Europe. For the full year, pharma grew 10%, industrial grew 15% and academic and government grew 13%. Instruments grew 16% for the full year with liquid chromatography, mass spec, and TA system sales all up double-digits.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Waters Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 2.97k | 707.75 | 24.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Waters Corporation. More…
| Operations | Investing | Financing |
| 611.66 | -107.97 | -509.63 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Waters Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.28k | 2.78k | 8.54 |
Key Ratios Snapshot
Some of the financial key ratios for Waters Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 7.3% | 7.6% | 29.8% |
| FCF Margin | ROE | ROA |
| 14.4% | 124.6% | 16.9% |
Market Price
The stock opened at $341.0, but closed at $336.9, down by 0.7% from the previous closing price of $339.3. The company’s performance was generally in line with expectations, although the stock has faced some downward pressure since the release of the earnings report. Despite this, WATERS CORPORATION is still trading above its pre-earnings opening price of $341.0. Overall, WATERS CORPORATION’s fourth quarter FY 2022 earnings report reflects their strong position in the market and their ability to maintain consistent results in spite of some negative market pressures. Live Quote…
Analysis
GoodWhale has conducted a thorough analysis of WATERS CORPORATION‘s fundamentals and the results show that the company is strong in profitability, medium in asset, growth, and weak in dividend according to Star Chart. WATERS CORPORATION has an impressive health score of 9/10 with regard to its cashflows and debt, indicating that it is capable to sustain its operations in times of crisis. Based on our analysis, we have classified WATERS CORPORATION as ‘rhino’, a type of company that has achieved moderate revenue or earnings growth. Investors who are looking for stable returns and are willing to take on a moderate level of risk may be interested in such companies. WATERS CORPORATION’s low dividend yield, however, may be an indication that it is not a suitable option for those looking for high dividend returns. More…
Peers
Waters Corporation is an American analytical instrument manufacturing company that specializes in liquid chromatography, mass spectrometry, and thermal analysis instruments. It has annual sales of over $2 billion and employs more than 6,000 people worldwide. Its products are used in the life sciences, pharmaceutical, and chemical industries. Waters Corporation’s main competitors are IQVIA Holdings Inc, Agilent Technologies Inc, Vijaya Diagnostic Centre Ltd.
– IQVIA Holdings Inc ($NYSE:IQV)
The company’s market cap as of 2022 was 39.27B and its ROE was 21.52%. The company is a global provider of information, innovative technology solutions, and real-world insights that help customers improve their well-being. The company offers a broad range of products and services that enable customers to manage their health and wellbeing.
– Agilent Technologies Inc ($NYSE:A)
Agilent Technologies, Inc. is a provider of life sciences, diagnostics, and applied chemical markets solutions. It operates through three segments: Life Sciences and Applied Markets Group, Diagnostics and Genomics Group, and Agilent CrossLab Group. The Life Sciences and Applied Markets Group segment offers application solutions that include chromatography, mass spectrometry, chemical analysis, and cellular analysis. The Diagnostics and Genomics Group segment provides in vitro diagnostic products and services. The Agilent CrossLab Group segment offers a range of services and consumables. Agilent Technologies was founded in 1999 and is headquartered in Santa Clara, California.
– Vijaya Diagnostic Centre Ltd ($BSE:543350)
Vijaya Diagnostic Centre Ltd is a leading diagnostic centre in India with a market cap of 46.61B as of 2022. The company has a return on equity of 17.7%. The company offers a wide range of diagnostic services including X-rays, ultrasounds, MRI, and CT scans. The company also has a wide network of centres across India.
Summary
Investors may find WATERS CORPORATION an attractive investment opportunity following the company’s fourth quarter of FY 2022 earnings report. Total revenue increased by 5.0%, while net income rose by 2.6% compared to the same period a year earlier. The company has demonstrated consistent growth and profitability, making it an attractive option for investors looking for reliable returns. With a strong financial performance and long-term potential, WATERS CORPORATION is worth considering as a potential investment.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
